An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors is a PHASE1 clinical asset sponsored by NEC Bio B.V in Solid Tumor. SEO and diligence focus: NECVAX-NEO1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Solid Tumor
Modality: protein therapy
Target: NECVAX-NEO1
Sponsor: NEC Bio B.V
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: NECVAX-NEO1
View original source fields
Condition raw: Solid Tumor
Condition normalized: Solid Tumor
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: NECVAX-NEO1
Target normalized: NECVAX-NEO1